Versono Medical will be attending EuroPCR 2026 in Paris from 19–22 May, one of the world’s leading meetings in interventional cardiovascular medicine. The annual event brings together cardiologists, surgeons, researchers, nurses, and industry leaders for a scientific programme focused on the latest developments in the field.

Versono will be represented by CEO Finbar (Barry) Dolan and CTO Hugh O’Donoghue, who will share an update on the company’s FREEFLOW pivotal study.

The U.S.-based multi-centre study, evaluating the Prosonic System across five clinical sites, is now nearing completion. Finbar and Hugh will present on the “no cross, no treatment” challenge in complex peripheral arterial disease and how the Prosonic System is being developed to support intraluminal crossing through complex occlusions in challenging anatomy.

The team will also be available to discuss a future first-in-human pilot study evaluating the Prosonic System in coronary anatomies, planned to begin in early 2027.

EuroPCR provides an opportunity to engage with clinicians, collaborators, and industry partners, and the team looks forward to discussions throughout the congress.

To arrange a meeting with the Versono team during EuroPCR, please contact Alison Kavanagh at alison.kavanagh@versono.life or Hugh O’Donoghue at hugh.odonoghue@versono.life